
|Articles|August 20, 2007
Latebreakers: First-in-class CCR5 inhibitor OK'd
Maraviroc (Selzentry, Pfizer), the first CCR5 inhibitor, was recently approved following priority review by the FDA.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How the Delinking Model Can Drive Transparency, Avoid PBM Manipulation | NCPA 2025
2
Gaps Between Expectations and Effects on Long COVID Contribute to Trust in Vaccines
3
PCV21 Shows Cost Effectiveness Compared With PCV15, PCV13, and PPSV23
4
Pharmacies Should Be Proactive in Expanding Clinical Services, Reimbursement Pathways | NCPA 2025
5


























































































































































